SOLCO BIOMEDICAL HAS BEEN OFFICIALLY APPOINTED AS OUR NEW EXCLUSIVE DISTRIBUTOR FOR BAGUERA® C IN THE REPUBLIC OF KOREA.
On September 1st, 2023, Spineart SA entered into a distribution agreement with Solco Biomedical of Republic of Korea. Since January 1st, 2024, Solco is the sole distributor of BAGUERA® C, with exclusive commercialization rights in the Republic of Korea.
This partnership combines over 12 years of BAGUERA® C clinical experience with Solco’s extensive distribution network and 50 years of presence in the medical device environment.
About Spineart
Spineart is a privately held medical device company focused on simplifying the surgical act by designing, developing, and promoting safe and efficient solutions to spine surgeons, operating room teams, and patients. Spineart markets a complete portfolio, in 60 markets, combining traceable barcoded sterile packed implants with compact instrument sets, thus proudly promoting greater safety, cost-efficiency, and compliance at the hospital.
About Solco
Established in 1974, Solco Biomedical manufactures and distributes a wide range of medical devices and is listed on the KOSDAQ since 2000.
SPINEART SECURES MORE THAN CHF20 MILLION IN CONVERTIBLE FINANCING FOLLOWING COMPLETION OF BAGUERA® C IDE STUDIES ENROLLMENT
Spineart has successfully raised a CHF20 million convertible financing. The funding comes on the heels of the completion of enrollment in the two BAGUERA® C IDE studies, underlining Spineart's commitment to advancing spinal surgery through large scale investments in research and development. More than CHF15 million of the funding was contributed by existing shareholders and employees, with the remaining portion sourced from new investors, above its CHF20 million initial target.
"We are thrilled to announce the successful closure of our CHF20 million convertible financing round, which underscores the confidence and support of our investors in Spineart's vision and innovative technologies," said Jerome Trividic, CEO of Spineart. "The overwhelming participation from existing shareholders, as well as the addition of new investors, is a testament to the potential of our BAGUERA® C cervical disc prosthesis and our commitment to improve spinal surgery through enabling technologies and robotic navigation."
The proceeds from the financing round will be used for several strategic initiatives. These include investments in novel enabling technologies, continued follow-up of patients enrolled in the two BAGUERA® C IDE studies, completion by the end of 2024 of a new 43,000sqft / 4,300 m2 factory currently under construction near Geneva and the opening this summer of Spineart's new R&D and Training Center for Enabling Technologies in Dallas, Texas.
About the BAGUERA® C IDE studies:
The BAGUERA® C IDE studies are pivotal in evaluating the safety and efficacy of Spineart's innovative BAGUERA® C cervical disc prosthesis, designed to address degenerative cervical disc disorders. The completion of enrollment in these studies marks a crucial step forward in bringing this new technology to market in the United States.
SpinEM ROBOTICS AND SPINEART FORGE STRATEGIC PARTNERSHIP WITH €10 MILLION INVESTMENT
SpinEM Robotics, a leading deep tech startup specializing in cutting-edge navigation solutions for robotic spinal surgery, is thrilled to announce a significant milestone in its innovation journey. The company has successfully closed a Series A2 funding round, securing a €10 million ($11 million) strategic investment from Spineart, a global leader in spine surgery innovation.
This investment marks the beginning of an exciting development collaboration between SpinEM Robotics and Spineart. Together, the companies aim to revolutionize the field of spinal surgery by combining SpinEM Robotics’ advanced navigation and robotic assistance technology with Spineart’s expertise in surgical solutions. By focusing on improving accuracy and eliminating the reliance on 3D cameras in navigation and robotics, the partnership will address the evolving needs of surgeons and patients worldwide.
Stephane Morvan, CEO of SpinEM Robotics, highlighted the significance of the collaboration, stating: “Led by industry visionary Stéphane Lavallée, SpinEM Robotics has developed groundbreaking technologies that will redefine the standard of care in navigated and robotically enabled spinal surgery. Our solutions seamlessly integrate human-robot interfaces, enhancing surgical precision and efficiency.”
Jerome Trividic, CEO of Spineart, expressed his enthusiasm for the strategic partnership, stating, “We are excited to integrate SpinEM Robotics’ transformative navigation and robotics technology into our portfolio. This collaboration underscores our commitment to delivering innovative solutions that empower surgeons, hospitals, and, most importantly, enable patients’ return to active life.”
This strategic investment not only strengthens SpinEM Robotics’ position in the market but also leverages the synergies between SpinEM Robotics, Spineart, and the eCential Robotics open platform.
SPINEART APPOINTS LAURENT NODÉ-LANGLOIS AS CHIEF TECHNOLOGY OFFICER TO LEAD ENABLING TECHNOLOGIES BUSINESS UNIT
Geneva, Switzerland – June 28, 2024 – Spineart, a fast-growing company specialized in spine surgery innovation, is pleased to announce the appointment of Laurent Nodé-Langlois as Chief Technology Officer.
In his new role, Laurent will be based in the United States and will lead Spineart's strategic initiatives in enabling technologies, focusing on digital surgical planning, navigation and robotics.
Laurent joins Spineart with over 25 years of experience in biomechanics, surgical navigation, innovation and intellectual property. Prior to joining Spineart, he served as Managing Director at General Electric, playing a pivotal role in advancing GE Healthcare's 3D imaging and navigation technologies.
"We are delighted to welcome Laurent Nodé-Langlois to Spineart as our Chief Technology Officer," said Jerome Trividic, CEO of Spineart. "His extensive expertise and proven track record in leading transformative advancements in enabling technologies will be instrumental as we continue to innovate and expand our capabilities in spine surgery."
As Chief Technology Officer, Laurent will oversee Spineart's enabling technologies strategy, including managing our investments and collaborations with healthtech and deeptech startups, as well as enhancing Spineart's intellectual property portfolio. This strategic new Executive role underlines Spineart’s commitment to deliver cutting-edge solutions for spine surgeons worldwide.
"I am excited to join Spineart and lead the Enabling Technologies business unit at such a pivotal time in the industry," said Laurent Nodé-Langlois. "I look forward to leveraging my experience and collaborating with the talented team at Spineart and their partners to advance our technological capabilities and drive innovation that improves patient outcomes."
SPINEART PEEK CAGES & ROMEO®2 POSTERIOR THORACOLUMBAR FIXATION SYSTEM NOW MDR APPROVED!
Spineart is thrilled to share a key milestone for the company: the PEEK Posterior Lumbar JULIET® cages as well as our PEEK Cervical TRYPTIK® cages and our Open and Minimally Invasive Thoracolumbar Fixation System ROMEO®2 are now CE Marked under the MDR 2017/745 (Medical Device Regulation) by the notified body TUV Sud.
This is a step further towards our commitment to certify our complete portfolio under the MDR regulation by May 2024. To achieve this goal, we are fully invested in advancing our quality system and clinical studies.
What is MDR and why does it matter?
The MDR is the set of regulations that control the design, clinical, production and distribution steps of medical devices in Europe entering in effect in May 2024. A number of requirements, such as technical files and clinical investigations, must be met in order to be compliant, which in turn ensures a higher level of patient safety.
SPINEART TITANIUM CAGES: NOW MDR APPROVED!
Spineart is thrilled to share a key milestone for the company: the secured cervical and lumbar cages, SCARLET® AC-T and SCARLET® AL-T, and our Posterior Lumbar JULIET®Ti cages are now CE Marked under the MDR 2017/745 (Medical Device Regulation) by the notified body TUV Sud.
This is a step further towards our commitment to certify our complete portfolio under the MDR regulation by May 2024. To achieve this goal, we are fully invested in advancing our quality system and clinical studies.
What is MDR and why does it matter?
The MDR is the set of regulations that control the design, clinical, production and distribution steps of medical devices in Europe entering in effect in May 2024. A number of requirements, such as technical files and clinical investigations, must be met in order to be compliant, which in turn ensures a higher level of patient safety.